Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases
Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO
Rongtai Pharma Resubmits Hong Kong Listing Application as China's Third-Largest Digital Marketing and Supply Chain Service Provider in the Out-of-Hospital Market